Advertisement

Topics

Telomerase Reverse Transcriptase HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49 Pipeline Review, H2 2017 [Report Updated: 10102017] Prices from USD $3500

01:48 EST 13 Nov 2017 | BioPortfolio Report Blog

Telomerase Reverse Transcriptase HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49 Pipeline Review, H2 2017


Summary


According to the recently published report 'Telomerase Reverse Transcriptase Telomerase Reverse Transcriptase'; Telomerase Reverse Transcriptase HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49 pipeline Target constitutes close to 31 molecules. Out of which approximately 25 molecules are developed by companies and remaining by the universities/institutes.


Telomerase Reverse Transcriptase HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49 Telomerase reverse transcriptase is a catalytic subunit of the enzyme telomerase. Telomerase activity is regulated by a number of factors including telomerase complexassociated proteins, chaperones and polypeptide modifiers. It modulates Wnt signaling. It plays important role in aging and antiapoptosis.


The report 'Telomerase Reverse Transcriptase Telomerase Reverse Transcriptase' outlays comprehensive information on the Telomerase Reverse Transcriptase HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type; that are being developed by Companies / Universities.


It also reviews key players involved in Telomerase Reverse Transcriptase HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49 targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 8, 2, 1, 8 and 4 respectively. Similarly, the universities portfolio in Phase I, Preclinical and Discovery stages comprises 2, 3 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Cardiovascular, Hematological Disorders, Immunology, Male Health and Metabolic Disorders which include indications NonSmall Cell Lung Cancer, Breast Cancer, Prostate Cancer, Solid Tumor, Acute Myelocytic Leukemia AML, Acute Myeloblastic Leukemia, Alzheimer's Disease, Hepatocellular Carcinoma, Chronic Lymphocytic Leukemia CLL, Colorectal Cancer, Gastric Cancer, Glioblastoma Multiforme GBM, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Amyotrophic Lateral Sclerosis, Aplastic Anemia, Atherosclerosis, Benign Prostatic Hyperplasia, Bile Duct Cancer Cholangiocarcinoma, Blood Cancer, Cervical Cancer, Gastroesophageal GE Junction Carcinomas, Graft Versus Host Disease GVHD, Head And Neck Cancer Squamous Cell Carcinoma, Hormone Refractory Castration Resistant, AndrogenIndependent Prostate Cancer, HormoneSensitive Prostate Cancer, Leukemias, Metastatic Brain Tumor, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Metastatic Transitional Urothelial Tract Cancer, Muscle Invasive Bladder Cancer MIBC, Myelodysplastic Syndrome, Myelofibrosis, NonHodgkin Lymphoma, NonSmall Cell Lung Carcinoma, Pancreatic Ductal Adenocarcinoma, Premature Ageing and Renal Cell Carcinoma.


Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope


The report provides a snapshot of the global therapeutic landscape for Telomerase Reverse Transcriptase HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49

The report reviews Telomerase Reverse Transcriptase HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources

The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities

The report reviews key players involved in Telomerase Reverse Transcriptase HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49 targeted therapeutics and enlists all their major and minor projects

The report assesses Telomerase Reverse Transcriptase HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Telomerase Reverse Transcriptase HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49 targeted therapeutics


Reasons to buy


Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies

Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Telomerase Reverse Transcriptase HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Telomerase Reverse Transcriptase HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49 development landscape

Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Original Article: Telomerase Reverse Transcriptase HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49 Pipeline Review, H2 2017 [Report Updated: 10102017] Prices from USD $3500

NEXT ARTICLE

More From BioPortfolio on "Telomerase Reverse Transcriptase HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49 Pipeline Review, H2 2017 [Report Updated: 10102017] Prices from USD $3500"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Reverse Transcriptase
Reverse transcriptase (RT) is an enzyme used to generate complementary DNA (cDNA) from an RNA template, a process termed reverse transcription. It is mainly associated with retroviruses. RT inhibitors are widely used as antiretroviral drugs. RT activitie...

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...